Proposal No. 13-109

| Proposal for Task Force Consideration at the ISSC 2017 Biennial Meeting |  | <ul> <li>a. ⊠ Growing Area</li> <li>b. □ Harvesting/Handling/Distribution</li> <li>c. □ Administrative</li> </ul> |  |
|---|--|---|--|
| Submitter   | Executive Office   |   |  |
| Affiliation   | Interstate Shellfish Sanitation Conference (ISSC)  |   |  |
| Address Line 1  | 209 Dawson Road  |   |  |
| Address Line 2  | Suite 1  |   |  |
| City, State, Zip  | Columbia, SC 29223-1740  |   |  |
| Phone   | 803-788-7559   |   |  |
| Fax   | 803-788-7576   |   |  |
| Email   | issc@issc.org  |   |  |
| Proposal Subject  | Expanding the use of the Abraxis Shipboard ELISA for the determination of paralytic shellfish poisoning (PSP) toxins   |   |  |
| Specific NSSP   | Section IV. Guidance Documents   |   |  |
| Guide Reference   | Chapter II. Growing Areas .11 Approved NSSP Laboratory Tests   |   |  |
| Text of Proposal/<br>Requested Action                                   | 4. Approved Limited Use Methods for Marine Biotoxin Testing  |   |  |
|   | This submission presents the Abraxis Shipboard ELISA for paralytic shellfish poisoning (PSP) toxins as a screening method for consideration as an NSSP Approved Limited Use Method.  |   |  |
|   | Currently the Abraxis Shipboard ELISA is approved for limited use in conjunction with the Jellett Rapid Extraction (mixture of rubbing alcohol and vinegar) and specifically for the onboard testing protocol. This proposal presents more data on the Abraxis test using the rapid extraction and also provides new data and comparisons of the test when AOAC extractions (boiling with hydrochloric acid) are performed. The data presented supports expanding the use of the Abraxis Shipboard ELISA to (1) allow for the rapid extraction OR the AOAC extraction method and (2) allow the kit to be used as a screening method beyond the onboard screening protocol  |   |  |
| Public Health<br>Significance   | Paralytic shellfish poisoning intoxications result from the consumption of seafood (primarily bivalve molluses) contaminated with neurotoxins known as paralytic shellfish toxins (PSTs). To protect public health, harvesting closures are implemented when toxicity exceeds the guidance level of 80 micrograms saxitoxin equivalents per 100 grams of shellfish tissue. As such, accurate screening and analytical methods are needed to monitor shellfish toxicity for making decisions regarding opening and closing shellfish growing areas accordingly. While the Abraxis Shipboard ELISA is already an NSSP Approved Limited Use Method for PSP toxicity determination, being able to use AOAC extractions with this kit would allow for the same extraction to be used with this method during screening and with the MBA as necessary for confirmation (without requiring a second extraction). Further expanding the use of the method beyond the onboard screening protocol would be beneficial as it would make the Abraxis Shipboard ELISA available for use by monitoring laboratories. |   |  |
| Cost Information  | Each 96 well plate costs ~\$500.   |   |  |
| Action by 2013  |  | Recommended referral of Proposal 13-109 to an appropriate committee as  |  |
| Laboratory Method and<br>Quality Assurance<br>Review Committee          | determined by the Conference C   |   |  |

Proposal No. 13-109

| Action by 2013     | Recommended adoption of Laboratory Method and Quality Assurance Review             |  |
|--------------------|--|--|
| Task Force I       | Committee recommendation on Proposal 13-109.                                       |  |
| Action by 2013     | Adopted recommendation of 2013 Task Force I on Proposal 13-109.                    |  |
| General Assembly   |  |  |
| Action by FDA      | Concurred with Conference action on Proposal 13-109.                               |  |
| May 5, 2014        |  |  |
| Action by 2015     | Recommended referral of Proposal 13-109 to an appropriate committee as             |  |
| Laboratory Methods | determined by the Conference Chair until data that supports the use of the Abraxis |  |
| Review Committee   | ELISA beyond the use of the onboard procedure is made available.                   |  |
| Action by 2015     | Recommended adoption of Laboratory Methods Review Committee                        |  |
| Task Force I       | recommendation on Proposal 13-109.   |  |
| Action by 2015     | Adopted recommendation of Task Force I on Proposal 13-109.                         |  |
| General Assembly   |  |  |
| Action by FDA      | Concurred with Conference action on Proposal 13-109.                               |  |
| January 11, 2016   |  |  |